BACKGROUND: High out-of-pocket costs for prescription medications have been associated with poor patient outcomes. A previous study found that the Part D coverage gap was significantly associated with decreases in adherence and persistence for medications frequently used in patients undergoing dialysis. It is not known what effect the decreased use of prescription drugs associated with the coverage gap had on utilization and spending for other medical care.
1
Although dialysis effectively contributes to long-term survival, 2 morbidity and mortality of patients requiring dialysis remain high, especially due to high cardiovascular morbidity and mortality. 3, 4 The economic burden of ESRD is substantial. Patients on dialysis, who comprise less than 1% of all Medicare beneficiaries, consumed 6.4% of the U.S. Medicare budget in 2006. 1 Most persons on dialysis are eligible for Medicare benefits beginning in the fourth month after initial diagnosis. 5 In comparison with commercial insurance, Part D benefits are complex and have high levels of patient cost-sharing, including deductibles, coinsurance, and coverage gaps. 6 A controversial and unique aspect of the Part D benefit design is the coverage gap ("donut hole"), an interval during which
• Our previous study found that patients on dialysis who reached the coverage gap were significantly more likely to be nonadherent to medications for diabetes, hypertension, dyslipidemia, hyperphosphatemia, and hyperparathyroidism after reaching the coverage gap.
• Compared with patients who had a low-income subsidy (LIS), patients who reached the coverage gap without an LIS had significantly lower medication adherence and persistence levels.
• Cost-associated medication underuse has been associated with increased emergency department visits, psychiatric admissions, nursing facility admissions, and diminished health status in a non-Medicare population.
What is already known about this subject
• Reaching the Part D coverage gap was associated with increased out-of-pocket spending, increased medical service utilization and associated costs among Medicare beneficiaries receiving dialysis.
• Medicare incurred lower pharmacy costs for patients who reached the coverage gap (as patients bore a higher cost-sharing burden), but Medicare incurred higher hospitalization costs compared with those who had an LIS.
• During the 1-year follow-up period, patients who reached the coverage gap had increased risks of all-cause and cardiovascularrelated mortality compared with those with an LIS.
What this study adds
and Medicare Parts A and B claims. Medicare Part D data contain enrollment information and prescription drug claims for patients with ESRD with Part D benefits. Institutional review board approval was obtained from the University of Texas at Austin.
Study Population
We included subjects in the study if they (a) Under the Medicare Part D standard plan cost-sharing structure in place in 2007 (detailed in a previously published paper 18 ), the gap interval was defined as OOP spending on medications between $799 and $3,850, 6 where beneficiaries were responsible for all of their drug costs during this gap. 7 For this study, patients were categorized based on type of coverage: LIS versus non-LIS. The non-LIS group was then subcategorized into 3 cohorts based on their benefit phase at the end of the year. The resulting 4 cohorts were as follows: Cohort 1 (non-LIS patients who did not reach the coverage gap-initial coverage; paid OOP costs < $799); Cohort 2 (non-LIS patients who reached the coverage gap but not catastrophic coveragecoverage gap; paid ≥ $799 and < $3,850 OOP costs; Cohort 3 (non-LIS patients who reached catastrophic coverage-catastrophic coverage; paid OOP costs ≥ $3,850); and Cohort 4 (LIS patients -none reached the coverage gap).
Outcomes and Covariates
The outcomes in this study included medical care utilization, direct medical costs, and mortality. Medical service utilization and related costs were ascertained separately for hospitalizations, office visits, drugs, and other visits (i.e., home health agency, skilled nursing facility, or hospice) using respective inpatient, outpatient, physician/supplier, and pharmacy claims. Medical service utilization was measured by the mean number of visits for medical services. Medical costs per person per year were defined as the amounts that Medicare paid for all-cause and cardiovascular-related services during 2007. Cardiovascular-related costs were identified by occurrence of any cardiovascular conditions (Appendix A, available in online article). Finally, we measured all-cause and cardiovascularrelated mortality during 2008 (1-year follow-up period) after patients had exposure to a full year of Part D drug benefits. Cardiovascular-related mortality was identified using the methodology used by the USRDS. Previous studies indicated that increased drug cost-sharing has been associated with adverse consequences. [7] [8] [9] [10] In Medicare populations, the coverage gap has been associated with reduced medication adherence, likely because beneficiaries adopt costlowering strategies when entering the coverage gap. 7, [11] [12] [13] [14] Several studies have demonstrated the consequences of cost-related medication underuse in non-Medicare, including increased emergency department (ED) visits, psychiatric admissions, nursing facility admissions, and diminished health status. 10, 15, 16 Patients with ESRD are at particular risk of facing high outof-pocket (OOP) drug costs. 5, 17 About 60% of Part D enrollees on dialysis who did not receive a low-income subsidy (LIS) reached the coverage gap in 2007, 18 which was significantly higher when compared with 23% in the general Medicare program. 1, 5, 19 We previously reported that the coverage gap was significantly associated with cost-related nonadherence in dialysis patients. 18 The adverse clinical and economic consequences of cost-related nonadherence can be severe, costly, 11 and particularly acute for dialysis patients due to their comorbid conditions. 17 The Affordable Care Act (ACA) of 2010 contains provisions that gradually close the coverage gap by reducing the coinsurance in the donut hole until it reaches 25% in 2020. Before passage of the ACA, the Centers for Medicare & Medicaid Services (CMS) implemented the new Medicare bundled ESRD Prospective Payment System in 2011. 20 Under this system, a single bundled payment covers virtually all outpatient dialysisrelated services and products. The inclusion of dialysis-specific oral medications into the bundle has been deferred to 2024, which is 10 years later than originally planned. 21 With these important Part D benefit changes being implemented in Medicare beneficiaries on dialysis, a comprehensive evaluation of health and economic outcomes associated with the Part D benefit is needed.
The association between prescription drug cost-sharing and health outcomes in general populations has been widely studied, [10] [11] [12] [13] 22, 23 but the implications for persons receiving dialysis are unknown. This study aims to examine the associations between Part D prescription drug cost-sharing and health outcomes, including medical service utilization, direct medical costs, and mortality, for Medicare beneficiaries on dialysis.
■■ Methods Study Design
We conducted a retrospective study using data from the U.S. Renal Data System (USRDS) for Medicare-eligible subjects receiving dialysis. The USRDS is a national registry of subjects with ESRD based on Medicare claims submitted to CMS by providers. This database has near-universal inclusion of ESRD subjects in the United States. 1 The USRDS database includes Medicare enrollment history, death dates and causes, We controlled for potential confounders in 2 ways: (1) adjusting for potential confounders as covariates in regression models (unmatched adjusted model) and (2) using propensity score (PS)-matching and adjusting for covariates in a regression model (propensity score-matched adjusted model). For regression models, Cohort 4 served as the reference group because LIS enrollees do not face the coverage gap and they incur minimal OOP expenses compared with the other cohorts.
Covariates included in medical care utilization and cost models encompassed age, gender, race, region, primary disease causing ESRD, ESRD duration, Charlson Comorbidity Index (CCI) scores, 24 4 , and Cohort 3 vs. 4). We calculated PSs using logistic regression to estimate the predicted probability of being in a non-LIS group, adjusting for covariates that were included in the regression model. A 1:1 PS model was adopted using a caliper matching technique (caliper ≤ 0.05). PS-matched patient baseline characteristics were compared using paired t-tests, Wilcoxon signed rank tests, and McNemar's tests. A generalized estimating equation model was used to account for correlation between PS-matched groups. 29, 30 Medical service utilization and cost differences between patients in Cohorts 1, 2, and 3 and their matched LIS enrollees (Cohort 4) were measured as relative risks (RRs). To assess the relationship between Part D prescription drug costsharing and death during 2008 (1 year after 2007 exposure to benefit structure), a Cox proportional hazards regression model was used.
All statistical analyses were 2-tailed, with an a priori significance level of α = 0.05. All analyses were conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC) and Stata version 11.1 (Stata Corp., College Station, TX).
■■ Results

Patient Characteristics
A total of 11,732 patients met the inclusion criteria. The distribution among the cohorts was as follows: Cohort 1-3,678 non-LIS patients (31.4%) had OOP drug costs < $799; Cohort 2-4,349 non-LIS patients (37.1%) had OOP drug costs between $799 and $3,849; Cohort 3-1,310 non-LIS patients (11.2%) had OOP medication costs > $3,850; and Cohort 4-2,395 LIS patients (20.4%) had OOP medication costs < $799 (Appendix B, available in online article). Overall, patients in Cohorts 1, 2, and 3 were older and more likely to be white compared with patients in Cohort 4 ( Table 1) . After PS matching, paired samples included 2,060 patients for Cohort 1 and Cohort 4 each; 1,797 patients for Cohort 2 and Cohort 4 each; and 950 patients for Cohort 3 and Cohort 4 each. After PS matching, there were no statistically significant differences between the matched groups in terms of demographic and baseline clinical characteristics or pre-index medical care costs (all, P > 0.05) except for primary disease causing ESRD between Cohorts 2 and 4 (P = 0.03; Table 2 ). Table 3 displays adjusted rates (unmatched adjusted model) and adjusted RRs (propensity score-matched adjusted model) of medical service utilization. In the main cohorts (N = 11,732), compared with Cohort 4, patients in Cohort 2 had higher rates of hospitalization (1.71 vs. 1.61), outpatient visits (7.97 vs. 6.91), and other visits (1.19 vs. 1.09) and longer days in hospital stay (12.25 vs. 11.09 days) (P < 0.05). Patients in Cohort 1 (7.14 vs. 6.91) and Cohort 3 (7.70 vs. 6.91) also had a higher rate of outpatient visits, respectively, compared with those in Cohort 4, although there were no significant differences in hospitalization rates. In the PS-matched cohorts, patients who reached the coverage gap (Cohort 2) had higher rates of hospitalization (RR = 1.02, 95% CI = 0.94-1.10), outpatient visits 
Medical Service Utilization
TABLE 3
Adjusted Health Care Utilization of Study Cohorts by Part D Prescription Drug Cost-Sharing Structure During 2007
Cohort 1 ($57,832), Cohort 2 ($58,761), and Cohort 3 ($60,859) compared with the mean for Cohort 4 ($57,148). However, the adjusted mean cost for cardiovascular-related medical care for patients in Cohort 2 ($13,022) was $1,163 higher than the mean for those in Cohort 4 ($11,859) (P = 0.03), although no differences were observed for patients in Cohort 1 and Cohort 3 compared with those in Cohort 4. In the PS-matched cohorts, patients in Cohort 2 had 48% lower pharmacy costs (RR = 0.52, 95% CI = 0.49-0.55) and 4% lower dialysis costs (RR = 0.96, 95% CI = 0.94-0.99), but 9% higher hospitalization costs (RR = 1.09, 95% CI = 1.01-1.18) and 6% higher outpatient costs (1.06, 95% CI = 0.97-1.17). Patients in Cohort 1 had 72% lower pharmacy costs (RR = 0.28, 95% CI = 0.26-0.30) and 5% lower dialysis costs (RR = 0.95, 95% CI = 0.93-0.98) but other medical care costs were not different compared with those in Cohort 4. Patients in Cohort 3 had 26% higher pharmacy costs, but their other medical costs (e.g., hospitalization, outpatient, and other visits) were not different from those in Cohort 4. There were no significant differences in total medical costs or cardiovascularrelated medical costs between patients in Cohorts 1, 2, and 3 and Cohort 4 after matching.
(RR = 1.16, 95% CI = 1.08-1.25), and other visits (RR = 1.17, 95% CI = 1.03-1.32) compared with those who had an LIS (Cohort 4), although the higher rate of hospitalization was not statistically significant. Patients in Cohort 3 had a higher rate of outpatient visits compared with those in Cohort 4 (RR = 1.14, 95% CI = 1.03-1.25). There were no differences in medical care utilization between patients in Cohort 1 and Cohort 4. Table 4 shows adjusted means (unmatched adjusted model) and adjusted RRs (propensity score-matched adjusted model) of direct medical care costs. In the unmatched main cohorts, the adjusted mean pharmacy costs for patients in Cohort 1 ($1,840), Cohort 2 ($2,605), and Cohort 3 ($6,224) were $3,222 lower, $2,457 lower, and $1,182 higher, respectively, than the mean for patients in Cohort 4 (P < 0.001). The mean adjusted hospitalization costs for patients in Cohort 1 ($25,081), Cohort 2 ($25,869), and Cohort 3 ($26,541) were $1,499 (P = 0.09), $2,287 (P = 0.01), and $2,959 (P = 0.01) higher, respectively, compared with the mean for Cohort 4 ($23,582). There were no significant differences in the mean adjusted total medical costs for patients in on dialysis. These outcomes remained significant for the propensity score-matched adjusted models. Medicare incurred lower pharmacy costs for Cohort 2 patients (as patients bore a higher cost-sharing burden), but Medicare incurred higher hospitalization costs compared with those who had an LIS (Cohort 4). The savings in pharmacy costs from the coverage gap were offset by increases in the costs of hospitalization. Patients in Cohort 2 who reached the coverage gap without an LIS at the end of year had a higher risk of all-cause and cardiovascular-related mortality than patients who received an LIS in the following year. Our findings on patients who reached the coverage gap are consistent with previous studies in elderly populations. 10, 16 A high level of cost-sharing in elderly persons in Canada was associated with a reduction in the use of essential drugs and an increase in ED visits. 16 The results from a prospective U.S. study in the Medicare population indicated that individuals whose benefits were capped had lower levels of drug adherence and increased hospitalizations, ED visits, and deaths. 10 However, both studies were conducted before Part D was implemented. Unlike these studies, we focused on Medicare Part D beneficiaries categorized by benefit type and benefit phase to evaluate the effects of the coverage gap on health outcomes. In contrast to previous literature, Polinski et al. indicated that Part D beneficiaries with cardiovascular conditions who reached the coverage gap without subsidy were at increased risk for drug discontinuation, but their hospitalization and mortality rates did not differ compared with those who received subsidy. 31 Researchers noted that the follow-up period of 119 days was not long enough to detect the differences in outcomes. 31 Another recent study found that Part D enrollees' adherence decreased prior to the gap because patients anticipated that continued spending would make them more likely to reach the gap and possibly affect their health outcomes. 
Direct Medical Care Costs
All-Cause and Cardiovascular-Related Mortality Rates of Study Cohorts by Part D Prescription Drug Cost-Sharing Structure During 2008
It was important to follow patients for the first full year of coverage, since patients may reduce their adherence before they reach the coverage gap, which may be reflected in their medical service utilization and costs throughout the year. Another 1-year follow-up period was used to evaluate whether mortality rates were associated with the previous year's Part D benefit type and benefit phase. We included patients who did not reach the coverage gap (Cohort 1) and those who entered and exited the coverage gap (Cohort 3). After PS matching, surprisingly, patients in Cohort 1 had a significantly higher risk of all-cause and cardiovascular-related mortality, but no difference was observed for patients in Cohort 3 and Cohort 4. Our previous study findings on adherence and persistence may help explain this trend; after adjustment for the covariates, patients in Cohort 1 (initial coverage) had the lowest adherence and persistence, while those in Cohort 3 (catastrophic coverage) had the highest adherence and persistence among the 4 Cohorts. 18 Overall, our study supports a rationale for eliminating the coverage gap in the Part D plan design because the existence of coverage gaps was associated with increased hospitalization costs and mortality. Our results also suggest that to evaluate the effects of the coverage gap, it is important to consider not only patients who reached the coverage gap (Cohort 2), but also patients who did not reach it (Cohort 1) but may have reduced their medication use because they anticipated being close to the coverage gap. In addition, our study supports the recent delay of the bundling implementation for dialysis-specific oral medications, which will give the CMS time to further evaluate and implement a policy that ensures access to care while recognizing the need for continued quality of care for Medicare beneficiaries on dialysis. Given the results we observed, policy decision makers should be sensitive to the deleterious effects of the coverage gap on health and economic outcomes and are encouraged to provide drug benefit policies that achieve intended clinical and economic goals.
Limitations
This study has some limitations that should be kept in mind when evaluating the results. While the standard benefit under Medicare Part D was used to classify patients, the exact plan in which an individual was enrolled is unknown. The structure of the standard Part D plans used for this study may differ from some subjects' nonstandard plans, which may have no deductible or generic coverage during the coverage gap. It was reported that among the 23 million beneficiaries enrolled in a Part D plan in 2006, approximately 89% enrolled in a plan without gap coverage, with the remainder enrolled in more generous plans.
33
For this study we used actual OOP drug spending to categorize patients, which indicated actuarially equivalent OOP spending before reaching the coverage gap, regardless of plan type. In this study, most OOP drug spending was observed for phosphate binders and cinacalcet-for which generics are not available. Thus, generic gap coverage would have a limited impact on OOP spending, and relatively few individuals have insurance for branded medication during the coverage gap.
We used a cross-sectional comparison for the assessment of health outcomes. Reverse causality or simultaneity between OOP drug costs and outcomes may exist among Part D non-LIS enrollees (Cohorts 1, 2, and 3 ). To avoid a reverse causality bias, we used Cohort 4 (LIS patients) as the reference group for regression and PS matching, as their cost-sharing did not vary. We cannot infer a causal relationship between the Part D coverage gap and the unintended clinical and economic outcomes; only associations were assessed. The propensity score-matched adjusted analyses controlled for possible confounders among the 4 cohorts, but we cannot rule out unmeasured confounding. Additional demographic and laboratory data were not available in our dataset, which may affect patients' health outcomes. Furthermore, patients may have filled prescriptions outside the Part D benefit, but exclusion of dual-eligible subjects, those who received a retiree drug subsidy, or those who had employer-sponsored health benefits might have kept such instances to a minimum. 34 Lastly, we used Part D standard plan cost-sharing structures in place in 2007 and restricted our cohorts to patients who survived during 2007. Thus, based on our findings from only 1 year of Part D coverage, extrapolation to a different year or to those who died before the end of the enrollment year or generalization to dialysis patients not enrolled in Part D may not be appropriate.
■■ Conclusions
Reaching the Part D coverage gap (Cohort 2) was associated with increased OOP spending, increased medical service utilization and costs, and increased mortality among Medicare beneficiaries receiving dialysis. These findings raise concern that the lack of drug coverage could lead to adverse health consequence for financially vulnerable persons. Providing adequate coverage for critical medications could reduce unintended consequences in Medicare beneficiaries on dialysis.
